HIV/AIDSPEBRANCT03969030
Peer-Educator-coordinated vs Nurse-coordinated ART Refill for Adolescents and Young Adults Living With HIV in Lesotho
A study testing PEBRA model in people with HIV/AIDS, run by Amstutz Alain at 20 sites in Lesotho.
Trial summary
Sub-Saharan Africa (SSA) is home to 85% of the adolescents and young people living with HIV (AYPLHIV) globally and they are heavily affected by the HIV/AIDS epidemic: AYPLHIV in SSA are the only population group for whom HIV-related mortality continues to increase, and they have overall poorer outcomes than all other… Read more about this study
- Who is it for?
- Ages 15 to 24 years
- Conditions the study is for
- HIV/AIDS
- What is being tested?
- PEBRA model
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 307 participants
- Where
- 20 sitesLesotho
- Study dates
- 1 Nov 2019to 30 Apr 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 24 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- the cluster is a public or missionary health center from the study districts, that offers ART services
- the cluster has at least one PE who is willing to participate and fulfills the following criteria:
- underwent the Sentebale Peer-Educator two-weeks training
- attended and successfully passed the study training assessment
Who cannot join
- health facility authority opposed to trial participation (verbal assent)
- the health facility is a hospital
- the health facility is situated in an area without cellphone signal
- Eligibility - individuals
- Individual is living with HIV and in care in a participating cluster
- Individual is 15-24 years old (AYPLHIV)
- Informed consent given
- Declares to seek the next follow-up visit at the same health facility
Trial locations and contacts
20 sites in 1 country.
20 sites in 1 country
Lesotho20 sites
Boiketsiso HC
Butha-Buthe, 400
Linakeng HC
Butha-Buthe, 400
Makhunoane HC
Butha-Buthe, 400
Motete HC
Butha-Buthe, 400
Muela HC
Butha-Buthe, 400
Ngoajane HC
Butha-Buthe, 400
Rampai HC
Butha-Buthe, 400
St. Paul HC
Butha-Buthe, 400
St. Peters HC
Butha-Buthe, 400
Tsime HC
Butha-Buthe, 400
Ha Lejone HC
Hlotse
Pontmain
Hlotse
Libibing HC
Mokhotlong
Linakaneng HC
Mokhotlong
Malefiloane HC
Mokhotlong
Mapholaneng HC
Mokhotlong
Moeketsane HC
Mokhotlong
Molikaliko HC
Mokhotlong
St. James HC
Mokhotlong
St. Martins HC
Mokhotlong
About this study
Official title: Peer-Educator-coordinated vs Nurse-coordinated ART Refill for Adolescents and Young Adults Living With HIV in Lesotho - a Cluster Randomized Clinical Trial (PEBRA Trial)
Sub-Saharan Africa (SSA) is home to 85% of the adolescents and young people living with HIV (AYPLHIV) globally and they are heavily affected by the HIV/AIDS epidemic: AYPLHIV in SSA are the only population group for whom HIV-related mortality continues to increase, and they have overall poorer outcomes than all other age groups. Lesotho with worldwide the second-highest HIV prevalence shows a viral suppression rate among AYPLHIV of only 49%.
In order to address the multiple barriers in the adolescent HIV care cascade and their unique needs, multicomponent packages of differentiated service delivery (DSD) are a promising approach.
Read more
In close collaboration with different local stakeholders, the researchers designed a DSD model specifically for AYPLHIV, called the PEBRA model. In the PEBRA model the peer-educator (PE) plays a pivotal role, by coordinating the ART refill/care according to the patient's preferences using a tablet-based application, called PEBRApp (https://github.com/chrisly-bear/PEBRApp). The PEBRApp helps the PE to assess each participant's preference, to adapt the ART refill according to these preferences in a feasible manner, to keep track of the ART refill, and to ensure regular contact between the PE and the participant. The model includes key innovative options such as individualized automatic SMS notifications and decentralized ART delivery.
The PEBRApp was developed with ❤️ by Technify Maseru, Lesotho (www.technifyls.com) \& Christoph Schwizer Zurich, Switzerland (www.christophschwizer.ch).
Read the detailed description
STUDY DESIGN
PEBRA study is a cluster randomized, open-label, superiority trial in a resource-limited setting. The rational for a cluster randomized design with health facilities as clusters, is the high risk of cross-contamination between the study arms if randomization would be done at individual level. The clusters (health facilities) will be randomized (randomly-varying block sizes, 1:1 allocation) into the 2 groups using a computer-generated randomization list, stratified by district and size of the AYPLHIV cohort of each facility (<15 vs ≥15). The study will be conducted at 20 health facilities in three districts of Lesotho (Leribe, Butha-Buthe, Mokhotlong).
OBJECTIVES
The overall objective of this study is to evaluate the feasibility and effectiveness of a DSD model ("PEBRA model") among AYPLHIV.
As primary objective this study seeks to assess the rate of viral suppression among AYPLHIV 12 months after enrolment between the intervention clusters, where AYPLHIV were offered the PEBRA model, and the control clusters, where AYPLHIV were offered standard of care.
Secondary objectives include a comparison of adherence to ART, the level of perceived quality of ART care and patient service satisfaction, engagement in care, viral suppression, lost-to-follow-up (LTFU), mortality, and transfer out between the intervention and control clusters. Further objectives include a cost-effectiveness evaluation and qualitative research regarding acceptance, scalability and feasibility of the DSD model.
QUALITATIVE RESEARCH
Besides above outlined qualitative research (QoL, QoC, longitudinal description of participants' preference assessments) the researchers will explore the acceptability of the PEBRA model in a) Focus Group Dis-cussions (FGD) with study participants from the intervention clusters, and b) key informant interviews (KII) with the main stakeholders (District Health Management Team and different health center staff). We plan to conduct at least 2 FGD (with about 5 study participants) per district and 3 KII per district, ac-cording to the concept of saturation. Data will be collected by trained facilitators using piloted interview questionnaires and discussion guides, in the local language (Sesotho). Qualitative data will be record-ed, transcribed, translated into English and coded and analyzed using the Framework Method. All participants in this qualitative research will be required to sign a separate consent form to participate and to be recorded. These consent forms and interview questionnaires will be submitted as an amendment to the ethics committee in Lesotho at a later stage.
COST-EFFECTIVENESS ANALYSIS AND SYSTEM IMPACT EVALUATION
The researchers will perform a system impact evaluation and cost-effectiveness analysis, in order to estimate the im-pact of the PEBRA model on health benefits and costs. First, we will assess the direct costs of the PEBRA model. Secondly, we will assess the cost-effectiveness of the PEBRA model. Thirdly, we will as-sess the economic burden of the PEBRA model to the study participants, i.e. including both direct costs and the opportunity costs of their time. The assessment of direct costs includes staff costs (PEs, clinic staff, VHWs), personnel training costs (especially for the PEs), the cost of equipment needed (PEBRApp, logistics), medical costs to the participant (medication, laboratory tests, consumables, etc.), and non-medical costs to the participant (i.e. cost of transportation to ART service). Data to assess pa-tient level costs will be collected from a randomly selected sub-sample of study participants from each cluster arm, using medical expenditure records and interviews. Cost outcomes will include:
- The average cost to the service provider per patient achieving the primary endpoint at 12 months in each cluster arm ('per patient suppressed provider cost') ii) The average cost to the patient per patient achieving the primary endpoint at 12 months in each cluster arm ('per patient suppressed patient cost') iii) The annual cost per patient in each cluster arm ('per patient year cost') iv) The cost-effectiveness of the PEBRA model with respect to viral suppression and engage-ment in care Costs will be reported as means (incl. standard deviations) and medians (incl. interquartile range) in local currency and US dollar and International Dollar.
PREFERENCE AND FEASIBILITY ASSESSMENT
The researchers will systematically assess the following exploratory analyses regarding feasibility and youth ART service preference:
- Youth ART service preferences: Longitudinal description of participants' preference assessments
- Feasibility of youth ART service according to preferences: Percentage of ART service delivered according to participants' preferences
- Differentiated Impact of the different support options on key study outcomes
PILOT TRIAL
PEBRA model will be piloted at one representative health facility in Butha-Buthe district, that will be pragmatically chosen in collaboration with the District Health Management Team. The pilot trial will be crucial to assess feasibility of the PEBRA model and the study procedures. The same procedures apply in the pilot trial as in the main trial, using the same consent process and baseline data collection. One PE will be specifically trained for the pilot. Recruitment for the pilot will be closed once 3-5 study participants are enrolled and follow-up will last for 2.5 months after having enrolled the last participant. All endpoints that are evaluable "at 3 months (range 2.5 - 3.5)" will be assessed and analyzed. The aim of the pilot trial is to give a first insight into PEBRA model and provide detailed information for the main trial.
- Conditions
- HIV/AIDS
- Being tested
- PEBRA model
- Keywords
- HIV, Sub-Sahara Africa, Lesotho, Differentiated Service Delivery, Adolescents and young adults living with HIV, ART service, Preference-based
- Medical subject headings
- Acquired Immunodeficiency Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PEBRA modelOther
The participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the PE, as much as feasible according to the participants' preferences. Thus, the preferences of each participant are captured at enrolment and after a strict schedule thereafter. The PE conducts the preference assessment using a tablet-based application, called PEBRApp, accoring to a specific schedule. First, the participant will be asked his/her preference regarding different domains of DSD (see below) and this will be entered into the PEBRApp. Secondly, the chosen preferences are assessed regarding feasibility with specific questions, as not all preference options are available to everyone all the time. The preference assessment entails the following three domains of DSD:
- ART Refill
- SMS notifications
- Support
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the Peer-Educator (PE) according to the participants' preferences, using a tablet-based application, called PEBRApp. The preference assessment entails the following three domains of DSD:
1. ART Refill
2. SMS notifications
3. Support In each of the domains, the participants' preferences will be assessed and the most feasible option will be selected. The PEBRApp not only helps the PE to assess each participants' preference, but also to keep track of the ART refill, and to ensure regular contact between the PE and the participant. The model includes key innovative options such as individualized automatic SMS notifications and decentralized ART delivery. Receives: Other: PEBRA model |
| Control | No intervention | Participants in the control clusters are offered standard of care: ART visit/refill is coordinated by the nurse, is mostly clinic-based, not adapted to youth, and differentiated according to clinical values (i.e. if VL suppressed then option of ART Refill in a Community Adherence Club). |
What is being measured
The primary outcome is the main question the study is designed to answer.
In care with documented viral suppression
In care with documented viral suppression at 12 months, defined as the proportion of participants in care with a documented VL <20 copies/mL 12 months (range: 9 - 15 months) after enrolment out of all participants enrolled
Measured: 12 months (range: 9 - 15 months) after enrolment
Secondary outcomes (9)
Adherence to ART at 3 months (range 2.5 - 3.5), 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Assessed by 4 different setting- and age-validated ART adherence questions:
- pill count: change in percentage
- "When was the last time you missed any medications?" (i) past week, ii) 1-2 weeks ago, iii) 3-4 weeks ago, iv) never): Dichotomous outcome missed doses vs. no missed doses in the past month
- "ART missed at two or more consecutive days within last month?" ("drug holiday" question)
- "How would you rate your adherence over the last month" (i) very poor, ii) poor, iii) fair, iv) good, v) very good, vi) excellent): Dichotomous outcome adherent vs non-adherent (anything less than 'excellent')
Measured: 3 months (range 2.5 - 3.5), 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Quality of Life (QoL) at 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Assessed by WHO QoL in PLHIV: WHO HIV QoL questionnaire (whoqol_hiv_bref questionnaire with 31 five-point Likert Scale items with categorical outcomes
Measured: 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Perceived quality of ART Care / patient service satisfaction at 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Assessed by a setting-validated QoC and patient service satisfaction questionnaire (12 five-point Likert Scale items with categorical outcome) by an external data collector, not the peer-educator
Measured: 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Engagement in care at 6 months
Engagement in care at 6 months, defined as the proportion of participants engaged in care 6 months (range 5 - 8) after enrolment out of all participants enrolled
Measured: 6 months (range 5 - 8) after enrolment
Alternative viral suppression at 12 months
Alternative viral suppression at 12 months, defined as the proportion of participants with a documented VL <1000 copies/mL 12 months (range 9 - 15) after enrolment out of all participants enrolled
Measured: 12 months (range 9 - 15) after enrolment
Engagement in care at 12 months
Engagement in care at 12 months, defined as the proportion of participants engaged in care 12 months (range 9 - 15) after enrolment out of all participants enrolled
Measured: 12 months (range 9 - 15) after enrolment
All-cause mortality
All-cause mortality at 6 and 12 months, defined as the proportion of participants dead 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment, respectively, out of all participants enrolled
Measured: 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
LTFU at 6 and 12 months
LTFU at 6 and 12 months, defined as the proportion of participants LTFU 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment, respectively, out of all participants enrolled
Measured: 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Transfer out at 6 and 12 months
Transfer out at 6 and 12 months, defined as the proportion of participants who transferred out to any other health facility (than the initially attached one) with known outcome (documented proof of follow-up visit or laboratory test) 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment, respectively, out of all participants enrolled
Measured: 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 May 2019
- Study start1 Nov 2019
- Primary completion30 Apr 2021
- Study completion30 Apr 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for HIV/AIDSStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- PEBRA study is a cluster randomized, open-label, superiority trial in a resource-limited setting
- Masking
- None (open label)
- Enrolment
- 307 participants (actual)
Sponsor and investigators
- Lead sponsor
- Amstutz Alain
- Sponsor type
- University, hospital or other
- Collaborators
- International AIDS Society (CIPHER grant), Swiss Tropical & Public Health Institute, SolidarMed, Sentebale, University of Basel, University Hospital, Basel, Switzerland, Swiss National Science Foundation
- Responsible party
- Sponsor-investigator, Amstutz Alain, Swiss Tropical & Public Health Institute
- Investigators
- Niklaus Labhardt, MD MIH, Study chair, Swiss TPH & University Hospital Basel & University of BaselAlain Amstutz, MD, Principal investigator, Swiss TPH & University Hospital Basel & University of BaselMathebe Kopo, Study director, SolidarMedJennifer Brown, MSc, Study director, Swiss TPH & University of BaselNadine Bachmann, MSc, Study director, Swiss TPH & University of BaselThabo Lejone, MIH, Study director, SolidarMedLebohang Sao, MD, Study director, DHMT BBTracy Glass, PhD, Study director, Swiss TPH & University of Basel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03969030
- Sponsor's protocol ID
- 2019-10
- Acronym
- PEBRA
- Status last verified
- May 2021
- First submitted
- 9 May 2019
- Last updated
- 2 Jun 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Seiler O, Kopo M, Kao M, Lejone TI, Tschumi N, Glass TR, Brown JA, Labhardt ND, Amstutz A. HIV Care Preferences among Young People Living with HIV in Lesotho: A Secondary Data Analysis of the PEBRA Cluster Randomized Trial. AIDS Res Treat. 2023 Apr 14;2023:8124192. doi: 10.1155/2023/8124192. eCollection 2023.
PubMed 39691584Kopo M, Lejone TI, Tschumi N, Glass TR, Kao M, Brown JA, Seiler O, Muhairwe J, Moletsane N, Labhardt ND, Amstutz A. Effectiveness of a peer educator-coordinated preference-based differentiated service delivery model on viral suppression among young people living with HIV in Lesotho: The PEBRA cluster-randomized trial. PLoS Med. 2023 Jan 3;20(1):e1004150. doi: 10.1371/journal.pmed.1004150. eCollection 2023 Jan.
PubMed 36595523Lejone TI, Kopo M, Bachmann N, Brown JA, Glass TR, Muhairwe J, Matsela T, Scherrer R, Chere L, Namane T, Labhardt ND, Amstutz A. PEBRA trial - effect of a peer-educator coordinated preference-based ART service delivery model on viral suppression among adolescents and young adults living with HIV: protocol of a cluster-randomized clinical trial in rural Lesotho. BMC Public Health. 2020 Mar 30;20(1):425. doi: 10.1186/s12889-020-08535-6.
PubMed 32228531
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Peer-Educator-coordinated vs Nurse-coordinated ART Refill for Adolescents and Young Adults Living With HIV in Lesotho - a Cluster Randomized Clinical Trial (PEBRA Trial)
- ClinicalTrials.gov ID
- NCT03969030
- Acronym / sponsor ID
- PEBRA / 2019-10
- Conditions
- HIV/AIDS
- Keywords
- HIV, Sub-Sahara Africa, Lesotho, Differentiated Service Delivery, Adolescents and young adults living with HIV, ART service, Preference-based
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 307 participants (actual)
- Lead sponsor
- Amstutz AlainUniversity, hospital or other
- Collaborators
- International AIDS Society (CIPHER grant), Swiss Tropical & Public Health Institute, SolidarMed, Sentebale, University of Basel, University Hospital, Basel, Switzerland, Swiss National Science Foundation
- Study start
- 1 Nov 2019 (actual)
- Primary completion
- 30 Apr 2021 (actual)
- Study completion
- 30 Apr 2021 (actual)
- First posted
- 31 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sub-Saharan Africa (SSA) is home to 85% of the adolescents and young people living with HIV (AYPLHIV) globally and they are heavily affected by the HIV/AIDS epidemic: AYPLHIV in SSA are the only population group for whom HIV-related mortality continues to increase, and they have overall poorer outcomes than all other age groups. Lesotho with worldwide the second-highest HIV prevalence shows a viral suppression rate among AYPLHIV of only 49%.
In order to address the multiple barriers in the adolescent HIV care cascade and their unique needs, multicomponent packages of differentiated service delivery (DSD) are a promising approach.
In close collaboration with different local stakeholders, the researchers designed a DSD model specifically for AYPLHIV, called the PEBRA model. In the PEBRA model the peer-educator (PE) plays a pivotal role, by coordinating the ART refill/care according to the patient's preferences using a tablet-based application, called PEBRApp (https://github.com/chrisly-bear/PEBRApp). The PEBRApp helps the PE to assess each participant's preference, to adapt the ART refill according to these preferences in a feasible manner, to keep track of the ART refill, and to ensure regular contact between the PE and the participant. The model includes key innovative options such as individualized automatic SMS notifications and decentralized ART delivery.
The PEBRApp was developed with ❤️ by Technify Maseru, Lesotho (www.technifyls.com) \& Christoph Schwizer Zurich, Switzerland (www.christophschwizer.ch).
Detailed description
STUDY DESIGN
PEBRA study is a cluster randomized, open-label, superiority trial in a resource-limited setting. The rational for a cluster randomized design with health facilities as clusters, is the high risk of cross-contamination between the study arms if randomization would be done at individual level. The clusters (health facilities) will be randomized (randomly-varying block sizes, 1:1 allocation) into the 2 groups using a computer-generated randomization list, stratified by district and size of the AYPLHIV cohort of each facility (<15 vs ≥15). The study will be conducted at 20 health facilities in three districts of Lesotho (Leribe, Butha-Buthe, Mokhotlong).
OBJECTIVES
The overall objective of this study is to evaluate the feasibility and effectiveness of a DSD model ("PEBRA model") among AYPLHIV.
As primary objective this study seeks to assess the rate of viral suppression among AYPLHIV 12 months after enrolment between the intervention clusters, where AYPLHIV were offered the PEBRA model, and the control clusters, where AYPLHIV were offered standard of care.
Secondary objectives include a comparison of adherence to ART, the level of perceived quality of ART care and patient service satisfaction, engagement in care, viral suppression, lost-to-follow-up (LTFU), mortality, and transfer out between the intervention and control clusters. Further objectives include a cost-effectiveness evaluation and qualitative research regarding acceptance, scalability and feasibility of the DSD model.
QUALITATIVE RESEARCH
Besides above outlined qualitative research (QoL, QoC, longitudinal description of participants' preference assessments) the researchers will explore the acceptability of the PEBRA model in a) Focus Group Dis-cussions (FGD) with study participants from the intervention clusters, and b) key informant interviews (KII) with the main stakeholders (District Health Management Team and different health center staff). We plan to conduct at least 2 FGD (with about 5 study participants) per district and 3 KII per district, ac-cording to the concept of saturation. Data will be collected by trained facilitators using piloted interview questionnaires and discussion guides, in the local language (Sesotho). Qualitative data will be record-ed, transcribed, translated into English and coded and analyzed using the Framework Method. All participants in this qualitative research will be required to sign a separate consent form to participate and to be recorded. These consent forms and interview questionnaires will be submitted as an amendment to the ethics committee in Lesotho at a later stage.
COST-EFFECTIVENESS ANALYSIS AND SYSTEM IMPACT EVALUATION
The researchers will perform a system impact evaluation and cost-effectiveness analysis, in order to estimate the im-pact of the PEBRA model on health benefits and costs. First, we will assess the direct costs of the PEBRA model. Secondly, we will assess the cost-effectiveness of the PEBRA model. Thirdly, we will as-sess the economic burden of the PEBRA model to the study participants, i.e. including both direct costs and the opportunity costs of their time. The assessment of direct costs includes staff costs (PEs, clinic staff, VHWs), personnel training costs (especially for the PEs), the cost of equipment needed (PEBRApp, logistics), medical costs to the participant (medication, laboratory tests, consumables, etc.), and non-medical costs to the participant (i.e. cost of transportation to ART service). Data to assess pa-tient level costs will be collected from a randomly selected sub-sample of study participants from each cluster arm, using medical expenditure records and interviews. Cost outcomes will include:
- The average cost to the service provider per patient achieving the primary endpoint at 12 months in each cluster arm ('per patient suppressed provider cost') ii) The average cost to the patient per patient achieving the primary endpoint at 12 months in each cluster arm ('per patient suppressed patient cost') iii) The annual cost per patient in each cluster arm ('per patient year cost') iv) The cost-effectiveness of the PEBRA model with respect to viral suppression and engage-ment in care Costs will be reported as means (incl. standard deviations) and medians (incl. interquartile range) in local currency and US dollar and International Dollar.
PREFERENCE AND FEASIBILITY ASSESSMENT
The researchers will systematically assess the following exploratory analyses regarding feasibility and youth ART service preference:
- Youth ART service preferences: Longitudinal description of participants' preference assessments
- Feasibility of youth ART service according to preferences: Percentage of ART service delivered according to participants' preferences
- Differentiated Impact of the different support options on key study outcomes
PILOT TRIAL
PEBRA model will be piloted at one representative health facility in Butha-Buthe district, that will be pragmatically chosen in collaboration with the District Health Management Team. The pilot trial will be crucial to assess feasibility of the PEBRA model and the study procedures. The same procedures apply in the pilot trial as in the main trial, using the same consent process and baseline data collection. One PE will be specifically trained for the pilot. Recruitment for the pilot will be closed once 3-5 study participants are enrolled and follow-up will last for 2.5 months after having enrolled the last participant. All endpoints that are evaluable "at 3 months (range 2.5 - 3.5)" will be assessed and analyzed. The aim of the pilot trial is to give a first insight into PEBRA model and provide detailed information for the main trial.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- PEBRA study is a cluster randomized, open-label, superiority trial in a resource-limited setting
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Other: PEBRA modelParticipants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the Peer-Educator (PE) according to the participants' preferences, using a tablet-based application, called PEBRApp. The preference assessment entails the following three domains of DSD: 1. ART Refill 2. SMS notifications 3. Support In each of the domains, the participants' preferences will be assessed and the most feasible option will be selected. The PEBRApp not only helps the PE to assess each participants' preference, but also to keep track of the ART refill, and to ensure regular contact between the PE and the participant. The model includes key innovative options such as individualized automatic SMS notifications and decentralized ART delivery. |
| Control | No intervention | –Participants in the control clusters are offered standard of care: ART visit/refill is coordinated by the nurse, is mostly clinic-based, not adapted to youth, and differentiated according to clinical values (i.e. if VL suppressed then option of ART Refill in a Community Adherence Club). |
Who may qualify
- Ages
- 15 to 24 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (4 listed)
- the cluster is a public or missionary health center from the study districts, that offers ART services
- the cluster has at least one PE who is willing to participate and fulfills the following criteria:
Key exclusion criteria (8 listed)
- health facility authority opposed to trial participation (verbal assent)
- the health facility is a hospital
- the health facility is situated in an area without cellphone signal
- Eligibility - individuals
- Individual is living with HIV and in care in a participating cluster
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PEBRA modelThe participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the PE, as much as feasible according to the participants' preferences. Thus, the preferences of each participant are captured at enrolment and after a strict schedule thereafter. The PE conducts the preference assessment using a tablet-based application, called PEBRApp, accoring to a specific schedule. First, the participant will be asked his/her preference regarding different domains of DSD (see below) and this will be entered into the PEBRApp. Secondly, the chosen preferences are assessed regarding feasibility with specific questions, as not all preference options are available to everyone all the time. The preference assessment entails the following three domains of DSD: 1. ART Refill 2. SMS notifications 3. Support | Other | Intervention |
Primary outcome
In care with documented viral suppression
Time frame: 12 months (range: 9 - 15 months) after enrolment
In care with documented viral suppression at 12 months, defined as the proportion of participants in care with a documented VL <20 copies/mL 12 months (range: 9 - 15 months) after enrolment out of all participants enrolled
9 secondary outcomes
Adherence to ART at 3 months (range 2.5 - 3.5), 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Time frame: 3 months (range 2.5 - 3.5), 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Quality of Life (QoL) at 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Time frame: 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Perceived quality of ART Care / patient service satisfaction at 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Time frame: 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Engagement in care at 6 months
Time frame: 6 months (range 5 - 8) after enrolment
Alternative viral suppression at 12 months
Time frame: 12 months (range 9 - 15) after enrolment
Engagement in care at 12 months
Time frame: 12 months (range 9 - 15) after enrolment
All-cause mortality
Time frame: 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
LTFU at 6 and 12 months
Time frame: 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Transfer out at 6 and 12 months
Time frame: 6 months (range 5 - 8) and 12 months (range 9 - 15) after enrolment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2021.
- Derived from this study: PubMed 39691584Seiler O, Kopo M, Kao M, Lejone TI, Tschumi N, Glass TR, Brown JA, Labhardt ND, Amstutz A. HIV Care Preferences among Young People Living with HIV in Lesotho: A Secondary Data Analysis of the PEBRA Cluster Randomized Trial. AIDS Res Treat. 2023 Apr 14;2023:8124192. doi: 10.1155/2023/8124192. eCollection 2023.
- Derived from this study: PubMed 36595523Kopo M, Lejone TI, Tschumi N, Glass TR, Kao M, Brown JA, Seiler O, Muhairwe J, Moletsane N, Labhardt ND, Amstutz A. Effectiveness of a peer educator-coordinated preference-based differentiated service delivery model on viral suppression among young people living with HIV in Lesotho: The PEBRA cluster-randomized trial. PLoS Med. 2023 Jan 3;20(1):e1004150. doi: 10.1371/journal.pmed.1004150. eCollection 2023 Jan.
- Derived from this study: PubMed 32228531Lejone TI, Kopo M, Bachmann N, Brown JA, Glass TR, Muhairwe J, Matsela T, Scherrer R, Chere L, Namane T, Labhardt ND, Amstutz A. PEBRA trial - effect of a peer-educator coordinated preference-based ART service delivery model on viral suppression among adolescents and young adults living with HIV: protocol of a cluster-randomized clinical trial in rural Lesotho. BMC Public Health. 2020 Mar 30;20(1):425. doi: 10.1186/s12889-020-08535-6.
- PEBRAppLink provided by the sponsor.
- Individual participant dataSharing planned: Yes
Related trials for HIV/AIDS
Enrolling by invitation
ORCHID: An Online Intervention for Persons With HIV (Miami)
HIV/AIDS, HPV Infection
Recruiting
Enhancing the Organizational Social Context to Improve Viral Suppression and Retention in HIV Care
HIV/AIDS
RecruitingPhase 1/2
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
HIV Associated Neurocognitive Disorder, HIV Dementia
Recruiting
Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Randomized Trial
HIV/AIDS, HIV/AIDS Prevention
Active, not recruitingPhase 2
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Niklaus Labhardt, MD MIH study chair
Swiss TPH & University Hospital Basel & University of Basel
Alain Amstutz, MD principal investigator
Swiss TPH & University Hospital Basel & University of Basel
Mathebe Kopo study director
SolidarMed
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PEBRA model in people with HIV/AIDS, run by Amstutz Alain at 20 sites in Lesotho.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in Lesotho. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
In care with documented viral suppression (time frame: 12 months (range: 9 - 15 months) after enrolment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03969030, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2021; AzTrials last refreshed its copy on 1 Nov 2026.